Berlirem GmbH
Berlirem is a Berlin (Germany) based pharmaceutical company dedicated to develop innovative concepts for the continuous parenteral application of Levodopa and related compounds to improve the therapy of Parkinson’s Disease. Established in 2014, Berlirem has spent a decade of research and development in this field.
Levodopa (LD) is highly effective in treating the symptoms of Parkinson’s Disease (PD) and has been the gold standard of PD therapy for more than 50 years. Yet, conventional oral LD therapy does not exploit the full therapeutic potential of this drug. There remains the unmet medical need for continuous drug delivery leading to more stable drug plasma levels.
To address this critical challenge of PD therapy, Berlirem´s R&D is developing prodrugs of levodopa as well as new treatment schedules for levodopa combinations effective in predictable and stable levodopa plasma levels meeting the requirements of a continuous dopaminergic stimulation (CDS).
As a result of several years of research with LD-prodrugs, Berlirem has invented a new application principle of sc-administered LD in combination with orally applied enzyme inhibitors (BRM-203). The patent-protected new application principle is effective with any water-soluble LD-source and increases LD plasma levels by a factor of 3 compared to competitive LD therapies at same dosage and route of administration.